ABBOTT INDIA | SUN PHARMA | ABBOTT INDIA/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 49.4 | 52.9 | 93.5% | View Chart |
P/BV | x | 14.4 | 4.5 | 319.5% | View Chart |
Dividend Yield | % | 1.5 | 1.1 | 131.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-22 |
SUN PHARMA Mar-22 |
ABBOTT INDIA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 23,902 | 931 | 2,567.7% | |
Low | Rs | 14,553 | 593 | 2,455.8% | |
Sales per share (Unadj.) | Rs | 2,315.0 | 161.1 | 1,436.9% | |
Earnings per share (Unadj.) | Rs | 375.9 | 14.2 | 2,647.9% | |
Cash flow per share (Unadj.) | Rs | 407.0 | 23.1 | 1,759.5% | |
Dividends per share (Unadj.) | Rs | 275.00 | 10.00 | 2,750.0% | |
Avg Dividend yield | % | 1.4 | 1.3 | 108.9% | |
Book value per share (Unadj.) | Rs | 1,306.2 | 200.1 | 652.8% | |
Shares outstanding (eoy) | m | 21.25 | 2,399.34 | 0.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 8.3 | 4.7 | 175.7% | |
Avg P/E ratio | x | 51.2 | 53.7 | 95.3% | |
P/CF ratio (eoy) | x | 47.2 | 32.9 | 143.5% | |
Price / Book Value ratio | x | 14.7 | 3.8 | 386.7% | |
Dividend payout | % | 73.2 | 70.4 | 103.9% | |
Avg Mkt Cap | Rs m | 408,573 | 1,827,693 | 22.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 5,795 | 73,008 | 7.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,193 | 386,545 | 12.7% | |
Other income | Rs m | 774 | 14,374 | 5.4% | |
Total revenues | Rs m | 49,967 | 400,919 | 12.5% | |
Gross profit | Rs m | 10,875 | 53,150 | 20.5% | |
Depreciation | Rs m | 661 | 21,437 | 3.1% | |
Interest | Rs m | 191 | 1,274 | 15.0% | |
Profit before tax | Rs m | 10,797 | 44,813 | 24.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,810 | 10,755 | 26.1% | |
Profit after tax | Rs m | 7,987 | 34,058 | 23.5% | |
Gross profit margin | % | 22.1 | 13.7 | 160.8% | |
Effective tax rate | % | 26.0 | 24.0 | 108.5% | |
Net profit margin | % | 16.2 | 8.8 | 184.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 38,530 | 350,150 | 11.0% | |
Current liabilities | Rs m | 12,032 | 172,006 | 7.0% | |
Net working cap to sales | % | 53.9 | 46.1 | 116.9% | |
Current ratio | x | 3.2 | 2.0 | 157.3% | |
Inventory Days | Days | 6 | 149 | 4.1% | |
Debtors Days | Days | 2 | 100 | 2.1% | |
Net fixed assets | Rs m | 3,541 | 318,882 | 1.1% | |
Share capital | Rs m | 213 | 2,399 | 8.9% | |
"Free" reserves | Rs m | 27,544 | 477,713 | 5.8% | |
Net worth | Rs m | 27,756 | 480,112 | 5.8% | |
Long term debt | Rs m | 0 | 2,299 | 0.0% | |
Total assets | Rs m | 42,072 | 669,032 | 6.3% | |
Interest coverage | x | 57.5 | 36.2 | 159.0% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.6 | 202.4% | |
Return on assets | % | 19.4 | 5.3 | 368.1% | |
Return on equity | % | 28.8 | 7.1 | 405.6% | |
Return on capital | % | 39.6 | 9.6 | 414.4% | |
Exports to sales | % | 0.7 | 0 | - | |
Imports to sales | % | 10.2 | 0 | - | |
Exports (fob) | Rs m | 350 | NA | - | |
Imports (cif) | Rs m | 5,034 | NA | - | |
Fx inflow | Rs m | 415 | 106,331 | 0.4% | |
Fx outflow | Rs m | 5,117 | 71,874 | 7.1% | |
Net fx | Rs m | -4,702 | 34,456 | -13.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,477 | 89,845 | 10.5% | |
From Investments | Rs m | -3,958 | -57,247 | 6.9% | |
From Financial Activity | Rs m | -6,374 | -51,935 | 12.3% | |
Net Cashflow | Rs m | -856 | -17,648 | 4.8% |
Indian Promoters | % | 0.0 | 54.5 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.2 | 34.6 | 23.5% | |
FIIs | % | 0.2 | 15.0 | 1.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.0 | 45.5 | 54.9% | |
Shareholders | 82,113 | 647,167 | 12.7% | ||
Pledged promoter(s) holding | % | 0.0 | 4.0 | - |
Compare ABBOTT INDIA With: CIPLA LUPIN DR. REDDYS LAB AUROBINDO PHARMA ZYDUS LIFESCIENCES
After opening the day on a flat note, Indian share markets turned volatile during the afternoon session and fell hard as selling was seen in banking and auto stocks.